GIPR is also expressed at low levels in nodose and dorsal root ganglia, but its function in these cell populations has not been examined (53, 6264)
Use of GLP-1 analogue drugs is associated with benefits but also health risks The use of glucagon-like peptide-1 receptor agonists (GLP-1RAs), used to treat diabetes and obesity, may be associated with a wide range of health effects, both positive - such as a reduced risk of cardiometabolic disorders - and negative - an increased risk of gastrointestinal conditions or hypertension
GLP-1sthat is, the class of drugs that includes semaglutide, packaged in brand-name form as Ozempic and Wegovy, and tirzepatide, like Mounjaroact on receptors in the body, and they improve insulin resistance, explains Judi Chervenak, MD, a reproductive endocrinologist at Montefiore with a clinical focus on menopause
Emerging research suggests potential benefits